Terence Fullerton

Efficacy and Safety of Oral Zavegepant in Migraine Prevention: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Migraine

Robert J. Fountaine, Sergey Dubrovin, Linda Mosher, Jing Liu et autres

This study aimed to assess the efficacy and safety of once daily oral zavegepant as a preventive treatment for chronic migraine. This multicenter, randomized, double-blind, placebo-controlled phase 2/3 study consisted of a 12-week double-blind treatment (DBT) phase and a 52-week open-label extension …

us (code pays fourni par la source)

Time Course of Effectiveness of Two Rimegepant Dosing Regimens for the Prevention of Episodic Migraine (P10-15.008)

David Kudrow, Andrew Charles, Robert Fountaine, Jeremias Antinew et autres

To evaluate the time course of effectiveness of 2 rimegepant (RIM) regimens for the preventive treatment of episodic migraine.

us (code pays fourni par la source)

Safety and Effectiveness of Rimegepant for Acute Treatment of Migraine in Adults Unsuitable for Triptan Use: Results from a 12-week Open-label Extension Phase. (P8-15.014)

Messoud Ashina, Peter McAllister, Charly Gaul, Adolfo Leyva-Rendón et autres

To evaluate safety and attack-to-attack reliability of rimegepant (RIM) for acute treatment of migraine over 12 weeks in adults unsuitable for triptans, and to explore changes in monthly migraine days (MMDs).

dk, us, mx, gb (code pays fourni par la source)

Rimegepant for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives: Results from a 12-week Open-label Extension Phase of a Randomized, Placebo-controlled Trial (P10-15.011)

Patricia Pozo-Rosich, Jose Gien-Lopez, Paweł Lisewski, Ayşe Neslihan Aslan et autres

Report findings from the open-label extension (OLE) phase of a multinational, randomized, placebo-controlled trial evaluating rimegepant for the prevention of episodic migraine in participants with a history of inadequate response to oral preventive medications (OPMs).

nl, us, gb (code pays fourni par la source)

Does rimegepant prevent migraine attacks in people who have not found other treatments taken by mouth (orally) to work well? A plain language summary of clinical study findings

Patricia Pozo-Rosich, José Antonio Gien López, Paweł Lisewski, Ayşe Neslihan Aslan et autres

Plain Language SummaryWhat is this summary about?Rimegepant is a treatment used by people in several countries to prevent migraine attacks. It is taken by mouth (orally). Several other oral treatments used to prevent migraine attacks were not designed for this purpose. They …

ps, es, pl, gb (code pays fourni par la source)

Can rimegepant stop symptoms of a migraine attack in people who have not found triptans to work well or are not recommended to use triptans? A plain language summary of a clinical study

Messoud Ashina, Peter McAllister, Charly Gaul, Adolfo Leyva-Rendón et autres

Plain Language SummaryWhat is this summary about?Rimegepant is a new medicine that can be used to prevent migraine attacks or stop a migraine attack that has already started. Many people with migraine have tried a type of medicine called a ‘triptan’ to …

dk, us, de, vn, gb (code pays fourni par la source)

Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial

Daniel Franjić, Robert J. Fountaine, Catherine Nalpas, Budhaditya Goswami et autres

Calcitonin gene-related peptide (CGRP) activation could play a causal role in the pathophysiology of chronic rhinosinusitis (CRS), a long-term inflammatory disease of the nasal cavity and paranasal sinuses. This study investigated the efficacy and safety of rimegepant 75 mg orally disintegrating tablet, …

us, fr, in (code pays fourni par la source)

Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study

Yasuhiko Matsumori, Shigekazu Kitamura, Toshimasa Yamamoto, Tomofumi Ishikawa et autres

BACKGROUND: The aim of the current analyses of a phase 3 randomized controlled trial conducted in Japan was to assess the long-term safety and effectiveness of rimegepant 75 mg, taken for up to 52 weeks, for the preventive treatment of migraine. METHODS: …

jp, us (code pays fourni par la source)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials

Larry Iv Charleston, Cynthia Armand, Teshamae S Monteith, Hope L. O'Brien et autres

OBJECTIVE: This post hoc subgroup analysis was conducted using pooled data from three US-based clinical trials to compare efficacy and safety of rimegepant 75 mg versus placebo in acute migraine in adults who are Black or African American. BACKGROUND: Migraine, characterized by …

us (code pays fourni par la source)

A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention

Jeremias Antinew, Robert J. Fountaine, Vittorio Loprinzo, Esther Straghan et autres

BACKGROUND: Rimegepant is a small-molecule calcitonin gene-related peptide receptor antagonist approved in adults for acute treatment of migraine (with or without aura) and preventive treatment of episodic migraine (EM). Rimegepant is well tolerated at approved doses; 75 mg as needed up to …

us, gb, it (code pays fourni par la source)

Plain Language Summary Publication: Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial

Shigekazu Kitamura, Yasuhiko Matsumori, Toshimasa Yamamoto, Tomofumi Ishikawa et autres

jp, us (code pays fourni par la source)

A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications

Patricia Pozo‐Rosich, José Antonio Gien López, Paweł Lisewski, Harpreet Seehra et autres

Aim This study aimed to evaluate the efficacy and tolerability of rimegepant for the prevention of episodic migraine in participants with a documented history of inadequate response to 2–4 categories of traditional oral preventive medication (OPM). Methods This multinational phase 4 trial …

ps, es, nl, us, gb (code pays fourni par la source)